XORTX Therapeutics Inc. (XRTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XRTX SEC filings page.
This page shows XORTX Therapeutics Inc. (XRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
XORTX Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
XORTX Therapeutics Inc. reported a net loss of $2.7M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
XORTX Therapeutics Inc. reported -$2.7M in net income in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
XORTX Therapeutics Inc. recorded an outflow of $2.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
XORTX Therapeutics Inc. held $865K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
XORTX Therapeutics Inc.'s ROE was -16.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
XORTX Therapeutics Inc. invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
XRTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Net Income | -$2.7M |
| Diluted Shares (Avg) | 5M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted).
XRTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Total Assets | $2.7M |
| Current Assets | $1.3M |
| Cash & Equivalents | $865K |
| Short-Term Investments | $0 |
| Long-Term Investments | $0 |
| Goodwill | $185K |
| Total Liabilities | -$13.8M |
| Total Equity | $16.5M |
| Retained Earnings | -$23.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
XRTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Operating Cash Flow | -$2.8M |
| Depreciation & Amortization | $112K |
| Capital Expenditures | $4K |
| Free Cash Flow | -$2.8M |
| Investing Cash Flow | -$295K |
| Financing Cash Flow | $1.4M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
XRTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F |
|---|---|
| Return on Equity | -16.1% |
| Return on Assets | -99.0% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| XORTX Therapeutics Inc. XRTX | FY2025 | N/A | -$2.7M | N/A | $3.1M | — |
| Quoin Pharmaceuticals, Ltd. QNRX | FY2025 | N/A | -$15.8M | N/A | $8.8M | — |
| Azitra Inc AZTR | FY2025 | $0 | -$11.0M | N/A | $7.1M | — |
| Jaguar Health, Inc. JAGX | FY2025 | $11.5M | -$54K | -0.5% | $2.4M | 33/100 |
| Theriva Biologics, Inc. TOVX | FY2025 | N/A | -$23.7M | N/A | $10.1M | — |
| Entero Therapeutics, Inc. ENTO | FY2025 | $36K | -$6.4M | N/A | $10.1M | — |
Where XORTX Therapeutics Inc. Ranks
Frequently Asked Questions
Is XORTX Therapeutics Inc. profitable?
No, XORTX Therapeutics Inc. (XRTX) reported a net income of -$2.7M in fiscal year 2025.
What is XORTX Therapeutics Inc.'s return on equity (ROE)?
XORTX Therapeutics Inc. (XRTX) has a return on equity of -16.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is XORTX Therapeutics Inc.'s free cash flow?
XORTX Therapeutics Inc. (XRTX) recorded an outflow of $2.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is XORTX Therapeutics Inc.'s operating cash flow?
XORTX Therapeutics Inc. (XRTX) recorded an outflow of $2.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are XORTX Therapeutics Inc.'s total assets?
XORTX Therapeutics Inc. (XRTX) had $2.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are XORTX Therapeutics Inc.'s capital expenditures?
XORTX Therapeutics Inc. (XRTX) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is XORTX Therapeutics Inc.'s return on assets (ROA)?
XORTX Therapeutics Inc. (XRTX) had a return on assets of -99.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is XORTX Therapeutics Inc.'s P/E ratio?
XORTX Therapeutics Inc. (XRTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is XORTX Therapeutics Inc.'s price-to-sales ratio?
XORTX Therapeutics Inc. (XRTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does XORTX Therapeutics Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, XORTX Therapeutics Inc. (XRTX) held $865K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.8M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Are XORTX Therapeutics Inc.'s earnings high quality?
XORTX Therapeutics Inc. (XRTX) reported a net loss of $2.7M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.